Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

544
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
544
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

480
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
480
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

489
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
489
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

571
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
571
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

310
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
310
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

535
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
535

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rheumatoid factor and anticitrullinated protein antibody status jointly influence the association between disease activity and cardiovascular risk in rheumatoid arthritis.

RMD open·2026
Same author

Derivation of a new index to reduce the occurrence of multiple positivity in line immunoassay for myositis specific autoantibodies in inflammatory myopathies.

Rheumatology international·2026
Same author

Monocyte/Macrophage Subsets in the Peripheral Blood, Their Related Cytokines, and Circulating Markers of Fibrosis in Active Takayasu Arteritis and Longitudinal Changes Following Immunosuppressive Therapy.

Journal of inflammation research·2026
Same author

Clinical Features and Outcome of Neuropsychiatric Manifestations in Juvenile Onset Systemic Lupus Erythematosus.

Indian journal of pediatrics·2026
Same author

Salvage therapy with JAK inhibitors in refractory Takayasu arteritis: a multicentre experience.

RMD open·2026
Same author

Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritis.

RMD open·2026

Related Experiment Video

Updated: Mar 22, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K

Management of Takayasu Arteritis - A 2026 Update.

Tanaz A Kermani1, Alessandro Tomelleri2, Daniele Scaramuzzi2

  • 1Division of Rheumatology, University of California Los Angeles (UCLA), Los Angeles, California, USA.

Current Rheumatology Reports
|March 20, 2026
PubMed
Summary

Recent advances in Takayasu arteritis (TAK) assessment include PETVAS and VAMP scores for disease activity and LVVID for damage. New treatments show promise, but more trials are needed.

Keywords:
AngiographyBiologicsDMARDsDamageDisease activityImagingPETRandomized controlled trialsTakayasu arteritisTreatment

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Novel and Innovative Hybrid Technique for Type A Aortic Dissection
06:26

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

1.2K

Related Experiment Videos

Last Updated: Mar 22, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.9K
Novel and Innovative Hybrid Technique for Type A Aortic Dissection
06:26

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

1.2K

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Background:

  • Takayasu arteritis (TAK) is a chronic large-vessel vasculitis affecting young women.
  • Vascular inflammation in TAK leads to stenosis, occlusion, and end-organ damage, impacting quality of life.

Purpose of the Study:

  • To review recent advances in assessing disease activity and damage in Takayasu arteritis.
  • To highlight current and emerging treatment strategies for TAK.

Main Methods:

  • Review of recent literature on Takayasu arteritis assessment and treatment.
  • Focus on novel imaging scores (PETVAS, VAMP) and composite indices (TAIDAI) for disease activity.
  • Evaluation of damage assessment tools (LVVID) and emerging biomarkers.

Main Results:

  • Distinguishing disease activity from damage in TAK remains challenging.
  • PETVAS, VAMP, TAIDAI show promise for assessing disease activity.
  • LVVID and serum fibrosis biomarkers are advances in damage assessment.
  • Conventional treatment involves glucocorticoids and DMARDs; newer agents like secukinumab, tofacitinib, and baricitinib show efficacy.
  • Vascular interventions are reserved for severe cases.

Conclusions:

  • Advances in composite tools for assessing disease activity and damage offer improved management potential for TAK patients.
  • High-quality clinical trials are essential to strengthen the evidence base for TAK treatment.